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Viral hepatitis in the United States has been a major
public health problem for many years, with estimated
medical treatment costs in the hundreds of millions of
dollars annually. The long-term consequences of many
of these viral infections are only now becoming appar-
ent to many infected patients and their families. Infec-
tions caused by the hepatitis C virus (HCV), in
particular, effectively resist the body’s attempts to de-
velop immunity, leading to persistent infection and
chronic liver disease in a large percentage of those
infected.
Thus, the declines in the incidence of hepatitis types
A, B, and C reported in recent years are encouraging.
This report summarizes surveillance data collected dur-
ing 1993 for acute viral hepatitis. Reported cases of vi-
ral hepatitis in 1993 continued their overall downward
trends with one exception. Hepatitis A increased by 5%
from 1992 to 1993, and preliminary data for 1994-95
suggest that this increase will continue into 1996.
The objective of national surveillance of viral hepati-
tis is to provide serologic, demographic, and
epidemiologic information that will aid in formulating
strategies and policies for the prevention and control of
these diseases. The hepatitis surveillance report inter-
prets and disseminates this information, presents new
developments in the field, and clarifies issues related to
viral hepatitis. Nationwide information on hepatitis is
obtained by two surveillance systems. In one, inci-
dence data are collected from cases reported to the Cen-
ters for Disease Control and Prevention (CDC)
National Notifiable Diseases Surveillance System
(NNDSS) by each state and territory. The etiologic clas-
sification is made by physician diagnosis; confirmation
by serologic testing is not required. The number of
cases and date reported of each type of hepatitis ap-
pear in the Morbidity and Mortality Weekly Report
(MMWR) and the MMWR Annual Summary of Notifi-
able Diseases, and are summarized in this report as
well.
In the other system, clinical, serologic and
epidemiologic data pertaining to risk factors of disease
acquisition are obtained from the Viral Hepatitis Sur-
veillance Program (VHSP), a separate reporting system
operated by the Hepatitis Branch, Division of Viral and
Rickettsial Diseases, National Center for Infectious Dis-
eases, CDC, Atlanta, Georgia. The VHSP obtains its in-
formation from the viral hepatitis case record, a copy
of which appears in the appendix. The case record was
revised in 1989. By 1993, 95% of cases were reported
with the revised form. This form (CDC 53.1) can be ob-
tained from the Hepatitis Branch. In addition, in 1991
several states began submitting their case reports via
electronic surveillance through the National Electronic
Telecommunications System for Surveillance (NETSS).
For states interested in using NETSS to report hepatitis
cases, the Hepatitis Branch and CDC’s Epidemiology
Program Office will provide technical support.
A third surveillance system referenced in this report
is the Sentinel Counties Study of Acute Viral Hepatitis,
a more intensive study of viral hepatitis in six counties
representative of the United States as a whole. This sur-
veillance system has provided nationally repre-
sentative data on acute viral hepatitis since 1982, and
has been a resource for detecting emerging infections
and performing more in-depth studies.
Surveillance data such as those reported here are de-
pendent on the cooperation of state and local health de-
partments, public health practitioners, and medical
care persons, reporting the diseases from their hospi-
tals, clinics, and offices. In recent years there has been a
decline in both the frequency of states reporting, and
the number of viral hepatitis cases reported to CDC
through the VHSP. Since 1989, the number of states re-
porting to the VHSP most (75%-100%) of the cases they
reported to NNDSS declined from 28 to 21, and an in-
creasing number of states have stopped reporting alto-
gether (see table on p. 22). In addition, the number of
reports received by VHSP of those reported to the
NNDSS has declined from 50% to 36%. The percentage
of NNDSS cases reported to the VHSP has dropped
particularly for hepatitis B and non-A,non-B (NANB)
hepatitis. For symptomatic serologically confirmed
hepatitis B, the VHSP received reports on only 26% of
the hepatitis B cases reported to NNDSS, and for symp-
tomatic, serologically confirmed NANB hepatitis, the
VHSP received reports on only 18% of the cases re-
ported to NNDSS.
CDC’s ability to accurately analyze and interpret na-
tionwide trends and patterns, identify high-risk
groups, and determine mechanisms of transmission for
each type of hepatitis depends on the cooperation of
the state and local health departments in reporting
laboratory and epidemiologic data to the VHSP. Key to
these tasks is the accurate determination of the specific
agent causing the viral hepatitis. Six distinct agents are
responsible for viral hepatitis worldwide; four have
been identified as endemic in the United States: hepati-
tis types A, B, C, and D. In 1993, hepatitis A accounted
for 56% of reported cases; hepatitis B, 31%, hepatitis
C/NANB, 11%; and hepatitis unspecified, 1%. Delta
hepatitis is not a reportable disease in the United
States, and occurs as a coinfection or superinfection
with hepatitis B.
The etiology of viral hepatitis cannot be determined
by clinical or epidemiologic characteristics alone. The
wide availability of diagnostic tests to characterize
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hepatitis A, hepatitis B, and hepatitis C makes the re-
porting of etiologic classification based on clinical and
epidemiologic characteristics obsolete and hinders the
clinical and public health management of patients with
these diseases. However, there are several limitations
of the serologic assay for HCV infection; some cases
caused by HCV may not develop antibody to HCV
(anti-HCV). Also, because patients with acute hepatitis
C may take 6 to 9 months to become anti-HCV posi-
tive, and because the anti-HCV assay does not distin-
guish between acute and chronic infection, diagnosis of
hepatitis C and NANB hepatitis both require serologic
exclusion of acute hepatitis A and hepatitis B. Report-
ing of NANB hepatitis should not be dependent on test-
ing for anti-HCV. 
Disease under reporting and inaccurate diagnosis
impede the public health community’s ability to de-
velop guidelines for preventing and controlling hepati-
tis and to assess the impact of these prevention
strategies. We thank those who have been actively con-




What is the risk of acquiring hepatitis C for health care workers and
what are the recommendations for prophylaxis and
follow-up after occupational exposure to hepatitis C virus?
Hepatitis C virus (HCV) is most efficiently transmit-
ted by large or repeated percutaneous exposures to
blood, such as through the transfusion of blood or
blood products from infectious donors and sharing of
contaminated needles among injection drug users.
Other blood-borne viruses, such as the hepatitis B virus
(HBV), are transmitted not only by overt percutaneous
exposures, but by mucous membrane and inapparent
parenteral exposures. Although these types of expo-
sures are prevalent among health-care workers, the
risk factors for HCV transmission in this occupational
setting are not well-defined. 
Occupational Transmission
A case-control study of patients with acute non-A,
non-B hepatitis, conducted prior to the discovery of
HCV, found a significant association between acquir-
ing disease and health-care employment, specifically
patient care or laboratory work (1). Seroprevalence
studies have reported antibody to HCV (anti-HCV)
rates of 1% among hospital-based health-care workers
in western countries (2). In the one study that assessed
risk factors for infection, a history of accidental needle
sticks was independently associated with anti-HCV po-
sitivity (3). Case reports have documented the transmis-
sion of HCV infection from anti-HCV positive patients
to health-care workers as a result of accidental needle
sticks or cuts with sharp instruments (2), and one re-
ported the transmission of HCV from a blood splash to
the conjunctiva (4). In follow-up studies of health-care
workers who sustained percutaneous exposures to
blood from anti-HCV positive patients, the incidence
of anti-HCV seroconversion (based on second-genera-
tion testing) averaged 3.5% (range, 0%-7%) (5-9); in the
one study that used polymerase chain reaction (PCR)
to measure HCV infection by detecting HCV RNA, the
incidence was 10% (5). 
Nosocomial Transmission
Nosocomial transmission of HCV is also possible if
breaks in technique occur or disinfection procedures
are inadequate and contaminated equipment is shared
between patients. Hospitalized patients may serve as a
reservoir for transmission; the prevalence of anti-HCV
among such patients has been reported to range from
2% to 18% (10-12). Case control studies have not found
an association between standard medical care proce-
dures and transmission of HCV in the United States
(1,13). However, in one report from Greece, 6 patients
with acute non-A, non-B hepatitis (5 of whom were
anti-HCV positive) all had onset of their disease within
a 9 day period, and all had been hospitalized 2 to 3
months previously at the same hospital; none had re-
ceived transfusions or undergone surgery (14). In Aus-
tralia, four patients who underwent outpatient surgery
on the same day became infected with HCV of the
same genotype as a chronically infected patient who
underwent surgery just prior to the cases (15). The fac-
tors responsible for transmission could not be identi-
fied, and none of the surgical personnel were anti-HCV
positive. In a report from Spain, however, five open
heart surgery patients with documented acute HCV in-
fection appeared to have acquired their infection from
a cardiovascular surgeon with chronic hepatitis C (16).
By sequence analysis, a high degree of homology was
demonstrated between the virus of the surgeon and
those of the patients. The factors responsible for trans-
mission were not identified.
Postexposure Prophylaxis
Unfortunately, postexposure prophylaxis with im-
mune globulin does not appear to be effective in pre-
venting hepatitis C. Historically, several studies have
attempted to assess the value of prophylaxis with im-
mune globulin for the prevention of posttransfusion
NANB hepatitis, but the results are difficult to com-
pare and interpret because of lack of uniformity in di-
agnostic criteria, mixed sources of donors (volunteer
and commercial), and different study designs (some
lack blinding and placebo controls). In some of these
studies, immune globulins seemed to reduce the rate of
clinical disease although not overall infection rates; in
one, patients receiving immune globulin were less
likely to develop chronic hepatitis. None of these data
have been reanalyzed since anti-HCV testing became
available, and in only one study was the first dose of
immune globulin given after, rather than before, the ex-
posure, making it difficult to assess its value for postex-
posure prophylaxis. 
At least 85% of persons with HCV infection become
chronically infected, and chronic liver disease with per-
sistently elevated liver enzymes develops in an average
of 67% (2). These extraordinarily high rates of chronic
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disease and persistent viremia in humans, as well as
animal transmission experiments demonstrating the
failure of antibody elicited by infection with one geno-
type to cross-neutralize either heterologous genotypes
or closely related but heterogeneous species within the
same genotype, indicate the absence of an effective neu-
tralizing immune response (17,18). Furthermore, im-
mune globulin is now manufactured from plasma that
has been screened for anti-HCV. A recently conducted
experimental study in chimpanzees found that im-
mune globulin manufactured from screened plasma ad-
ministered 1 hour after exposure to HCV did not
prevent infection or disease (19). In February 1994, the
Immunization Practices Advisory Committee reviewed
the available data and concluded that there was no sup-
port for the use of immune globulin for postexposure
prophylaxis of hepatitis C (CDC, unpublished data).
There is no information regarding the use of anti-viral
agents, such as alpha interferon, in the postexposure
setting, and such treatment is not recommended.
Issues Regarding Follow-Up After Exposure
In the absence of postexposure prophylaxis, multi-
ple issues need to be considered in deciding if there
should be a defined protocol for the follow-up of
health-care workers for HCV infection after occupa-
tional exposures. These areas include the limited data
on the risk of transmission, the limitations of available
serologic testing for detecting infection and determin-
ing infectivity, the poorly defined risk of transmission
by sexual, household, and perinatal exposures, the lim-
ited benefit of therapy for chronic disease, the cost of
follow-up, and the medical-legal implications. 
Although it seems clear that needle-stick exposure
to infectious blood is a risk factor for hepatitis C, and
that this risk appears to be intermediate between that
of HBV and human immunodeficiency virus, the data
are limited or nonexistent on the risk of transmission
associated with other types of occupational exposure.
This makes it difficult to provide health-care workers
who sustain such exposures with a meaningful esti-
mate of their chances of developing HCV infection.
Testing methods readily available in the clinical setting
also have limitations. With the commercially manufac-
tured enzyme immunoassays (EIAs) that detect anti-
HCV, there may be a prolonged interval between
exposure and seroconversion, although the average
time period is 8-10 weeks. In many populations, includ-
ing health-care workers, the rate of false positivity for
anti-HCV is high, and supplemental assays should al-
ways be used to judge the validity of repeatedly reac-
tive EIA results. About 5% to 10% of infections will not
be detected unless PCR is used to detect HCV RNA. Al-
though such assays for HCV RNA are available from
several commercial laboratories on a research-use ba-
sis, they are not standardized and the cost is high,
about $200 per test. Both false-positive and false-nega-
tive results can occur from improper handling and stor-
age or contamination of the test samples. In addition,
the detection of HCV RNA may be intermittent, and
the meaning of a single negative PCR test result is not
conclusive.
All anti-HCV-positive persons should be considered
potentially infectious, however, neither the presence of
antibody nor the presence of HCV RNA is a direct
measure of infectivity in settings where inapparent par-
enteral or mucosal exposures occur. Epidemiologic
studies have implicated exposure to infected sexual
and household contacts as well as to multiple sexual
partners in the transmission of HCV (1,13). Serologic
studies of the long-term sexual and household contacts
of patients with chronic hepatitis C have found evi-
dence of HCV infection in an average of 5% of sexual
partners and in an average of 3% of children (2). Stud-
ies of infants born to anti-HCV-positive mothers have
reported rates of perinatal transmission ranging from
0% to 13% (average 6%); in two small studies, only
mothers with “high” titers of HCV RNA transmitted
HCV to their infants (20,21). The inconsistent results of
these as well as studies that looked for HCV RNA in
body fluids other than serum and plasma may reflect
different concentrations of virus in the infected persons
sampled. The risk that an HCV-infected individual will
transmit the virus may be related to the type and size
of the inoculum and the route of transmission, as well
as the titer of virus, but data on the threshold concen-
tration of virus needed to transmit infection are insuffi-
cient. In the absence of such data and standardized
tests to measure infectivity, it is difficult to counsel anti-
HCV-positive persons about their risk of transmission
to others (22). Because the risk of HCV transmission be-
tween long-term steady sexual partners appears to be
low, there are no recommendations for changes in sex-
ual practices for persons with a steady sexual partner,
although infected persons should be informed of the
possible risk so they can decide if they wish to take pre-
cautions. Household articles such as toothbrushes and
razors should not be shared. There are no data to sup-
port discouraging either pregnancy or subsequent
breast feeding (see reference 22 for further details on
counseling)
The most obvious benefit from a follow-up protocol
would appear to be the opportunity for the health-care
worker to seek evaluation for chronic liver disease and
treatment, if eligible. Studies have shown that alpha in-
terferon therapy may have a beneficial effect among
some patients (23). In these studies, however, the pa-
tients were highly selected and therapy resulted in sus-
tained improvement in 20% or fewer of those treated;
no clinical, demographic, serum biochemical, serologic
or histologic features have been identified that reliably
predict which patients will respond to treatment and
sustain a long-term remission. The nationwide cost of
providing postexposure follow-up testing is estimated
at $2 to $4 million; the cost for each person who
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benefits from therapy is estimated at $200,000 (CDC,
unpublished data). 
Even in the absence of both available postexposure
prophylaxis and limited specific measures for disease
prevention, individual institutions should consider im-
plementing policies and procedures for follow-up after
percutaneous or per mucosal exposure to anti-HCV
positive blood to address individual workers’ concerns
about their risk and outcome. Above all, institutions
should ensure education of health-care providers re-
garding the risk and prevention of blood borne infec-
tions in the occupational setting (24), including
hepatitis C, and such information should be routinely
updated to ensure accuracy.
Summary Recommendations
 1. No postexposure prophylaxis is available for
hepatitis C; immune globulin is not recommended.
 2. Institutions should provide to health-care workers
accurate and up-to-date information on the risk
and prevention of all blood borne pathogens,
including hepatitis C.
 3. Institutions should consider implementing policies
and procedures for follow-up of health-care
workers after percutaneous or per mucosal
exposure to anti-HCV positive blood. Such
policies might include baseline testing of the
source for anti-HCV and baseline and 6 month
follow-up testing of the person exposed for
anti-HCV and ALT activity. All anti-HCV results
reported as repeatedly reactive by EIA should be
confirmed by supplemental anti-HCV testing.
 4. There are currently no recommendations
regarding restriction of health-care workers with
hepatitis C. The risk of transmission from an
infected worker to a patient appears to be very
low. Furthermore, there are no serologic assays
that can determine infectivity nor are there data to
determine the threshold concentration of virus
required for transmission. As recommended for all
health-care workers, those who are anti-HCV
positive should follow strict aseptic technique and
standard (universal) precautions, including
appropriate use of hand washing, protective
barriers, and care in the use and disposal of
needles and other sharp instruments.
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Is the recent increase in the reported cases of hepatitis C / NANB a real increase?
Introduction
The numbers of hepatitis C and non-A, non-B
(NANB) hepatitis cases reported in the United States
have fluctuated dramatically in the last 5 years, particu-
larly since tests for antibody to hepatitis C virus (anti-
HCV) were introduced in 1990. In addition, the
reported incidence of this disease has varied consider-
ably between different surveillance systems (Table 1).
The incidence of hepatitis C reported to the National
Electronic Telecommunications System for Surveillance
(NETSS) declined moderately from 1985 to 1990, but
then increased by almost 130% from 1990 to 1992. The
incidence rate in 1994 was still 73% higher than its 1990
level. In contrast, the incidence of hepatitis C in the Sen-
tinel Counties Study of Acute Viral Hepatitis (1), which
was initially 4-fold higher than the NETSS reported in-
cidence, declined by 80% from 1989 through 1989. A
similar decline was also observed in cases reported to
the Viral Hepatitis Surveillance Program (VHSP). Possi-
ble reasons for these discrepancies include the wide-
spread use of new diagnostic tests in laboratory-based
reporting. The increase in cases reported to NETSS
may have been the result of laboratory reports of
chronically infected patients, or anti-HCV positive pa-
tients identified through screening programs. To better
determine the reasons for these changes in nationwide
reporting, during July-August of 1995 the Hepatitis
Branch conducted a survey of a sample of county
health departments to determine their practices and
policies with regard to the reporting of hepatitis C and
NANB hepatitis cases.
Methods
Counties were selected as a stratified random sam-
ple of those counties that had reported at least one case
of hepatitis C/NANB in 1993. The selection list con-
sisted of 790 such counties, and a 20% sample of 161
counties was selected. Stratification of the sample by
population size ensured that large counties would
have a high probability of selection. 
Each county health department was asked to com-
plete a questionnaire that covered seven categories: re-
porting sources of data, case definitions, laboratory
reporting, follow-up for incomplete case reports, re-
sources for surveillance, uses to which data were put,
and information on respondents. 
Results
The data presented here are based on a preliminary
analysis of the first 90 questionnaires that were re-
turned. This represented an early response rate of 56%.














* National Electronic Telecommunications Systems for
* Surveillance
† Sentinel Counties Study of Acute Viral Hepatitis
Table 1. Reported Cases of Hepatitis C/non-A, non-B
Hepatitis per 100,000 Population in Two Surveillance
Systems, 1985-94
6 Issues and Answers
partments that had or had not responded, no
differences were found in population size or geo-
graphic location. Respondents included public health
nurses and epidemiologists. About half of the respon-
dents had worked at the health department for more
than 10 years.
Respondents cited hospitals (34%) as the most com-
mon source of case reports prior to 1991; laboratories
were next (20%). From 1991 to the present, they cited
laboratories as the most common source of case reports
(53%); hospitals were second (30%). Physicians were
cited as the third most common reporting source in
each period. Blood banks and other sources were cited
with similar rankings in each period.
Nearly half of the health departments surveyed did
not apply published case definition criteria when re-
porting acute hepatitis C/NANB cases. Fifty-six per-
cent of respondents said that a case would be reported
as hepatitis C/NANB on the basis of a physician’s diag-
nosis alone. Forty-nine percent said that they accepted
cases on the basis of laboratory reports alone. Discrete
dates of onset of symptoms were required by only 36%
of respondents, and exclusion of hepatitis A and B was
required by 40% of respondents. 
A large percentage of respondents said they fol-
lowed up on incomplete case reports; however, 39% of
these respondents also stated that they would accept
and report a case on the basis of a laboratory report
alone. When asked how they obtained the information
required to provide an accurate diagnosis, 96% of re-
spondents said they contacted the physician who made
the report. Sixty-eight percent did follow-up that in-
cluded contacting the patient. Only 39% determined if
supplemental testing was done on specimens that were
reported positive for anti-HCV.
Among the 23% of respondents who did not do fol-
low-up on incomplete case reports, 52% said other pub-
lic health problems took priority, while 50% cited lack
of personnel. Thirty-six percent cited the lack of any ef-
fective intervention for hepatitis C/NANB patients as a
reason.
Eighty-five percent of respondents reported in-
creases in the number of cases reported during the past
5 years, mostly owing to laboratory reporting of anti-
HCV positivity without evidence of acute disease.
Only 12% cited a true increase in the disease incidence
in their county or jurisdiction.
When asked to cite actions taken by the county
health department in response to reported cases of
hepatitis C/NANB, 77% of respondents said they pro-
vided counseling to patients. Thirty percent said they
published newsletters containing data on hepatitis
C/NANB.
We asked respondents to suggest ways that CDC
could improve reporting of hepatitis C/NANB. Most
pronounced was an expression of confusion regarding
what should be done with case reports of persons with
chronic hepatitis C/NANB. Many respondents felt that
CDC should publish a clearer, updated case definition.
Many also wanted guidelines from CDC for follow-up
of incomplete case reports. Respondents suggested that
CDC create educational programs targeting health-care
workers in an effort to increase the reporting of dis-
eases to the county health departments.
Summary. Since testing for anti-HCV became
widely available, county health departments have in-
creasingly relied on laboratories as sources of case re-
ports for hepatitis C/NANB. This has resulted in an
artifactual increase in the reported incidence of hepati-
tis C because of the reporting of anti-HCV- positive
persons with no clinical or epidemiologic evidence of
acute disease. Physician-reported cases continue to be
a small proportion of all reported hepatitis C/NANB
cases. In addition, many county health departments
confirmed that they pass these laboratory test positive
results on to the state health departments without suffi-
cient confirmation of acute disease. Primarily because
of lack of personnel and other diseases being seen as
higher priority, county health departments do not at-
tempt to obtain additional information necessary to
confirm acute disease. 
Further analysis of the survey results is being con-
ducted. Issues to be examined include the purpose of
surveillance of viral hepatitis; the importance of focus-
ing on acute, symptomatic disease to determine true in-
cidence; and the need for separate surveillance systems
to monitor patients with chronic infections and chronic
liver disease. Such surveillance efforts in the future will
depend on strict adherence to case definitions, and on
adequate resources to support them. The case
definition is shown on page 22 of this report.
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New Horizons
Evaluating the effectiveness of the programs to prevent
hepatitis B virus (HBV) transmission in the United States.
The Hepatitis Branch, in collaboration with the Na-
tional Immunization Program, has drafted disease re-
duction goals for the prevention of hepatitis B virus
(HBV) transmission in the United States (Table 1).
These goals were developed with comments from state-
based immunization staff and the Council of State and
Territorial Epidemiologists. Unlike other vaccine-pre-
ventable disease reduction targets, the targets for hepa-
titis B are not based on acute disease surveillance
reported through the National Notifiable Diseases Sur-
veillance System (NNDSS). Because most HBV infec-
tions in children <10 years of age are asymptomatic,
evaluation based on NNDSS data will not reliably
measure the effectiveness of hepatitis B vaccination
programs, especially those directed at infants. Assess-
ment of programs that target infants should primarily
be evaluated by vaccination coverage surveys. The util-
ity of various data sources, including coverage surveys,
population-based serologic surveys, and surveillance
for acute disease for evaluating all of the components
of hepatitis B prevention programs, will vary depend-
ing on the age-group targeted by the program (Table
2). As the data obtained by evaluation tools improves,
additional disease reduction targets can be proposed,
Perinatal Program
1. Goals for the reduction of perinatal HBV
infections in the United States.
By 2000, reduce the estimated number of peri-
natal infections by 80%, from 9,500 to 1,900.  
Objectives for HBsAg screening of pregnant
women
By 1998 ensure that:
every state has a law requiring HBsAg screen-
ing of all pregnant women. 
every state has developed a method to evaluate
HBsAg screening of pregnant women.
By 2000 ensure that:
90% of pregnant women are screened for
HBsAg prior to delivery.
Objectives for the identification and tracking of
infants born to HBsAg positive women.
By 2000, ensure that 
90% of the estimated 20,000 births to HBsAg-
positive pregnant women are identified each
year in the U.S.
90% of infants born to HBsAg-positive women
receive the first dose of hepatitis B vaccine and
hepatitis B immune globulin (HBIG) at birth.
90% of infants born to HBsAg-positive moth-
ers receive the remaining 2 doses of hepatitis
B vaccine by 6-8 months of age. 
2. Goals for the prevention of HBV transmission
in households of HBsAg-positive pregnant
women.
by 1998, every state should establish a pro-
gram to vaccinate household contacts of
HBsAg-positive pregnant women.
by 2000, >70% of household contacts are of-
fered hepatitis B vaccine each year.
Infant Vaccination Program
1. Goals for hepatitis B vaccination of infants
By the year 1998, ensure that 90% or more of
2 year-old children have received hepatitis B
vaccine. 
Interim objectives for hepatitis B vaccination
coverage of 2 year-old children 
By 1998, ensure that all states have devel-
oped activities to ensure that children in eth-
nically defined populations where HBV
infection is of high or intermediate en-
demicity (i.e., Alaskan Natives, Asian/Pa-
cific Islanders, infants born to first
generation immigrant/refugee women from
countries with a high/intermediate en-
demicity of HBV infection) are completely
vaccinated in the first 12 months of life.
Table 1. Disease Reduction Goals for Hepatitis B Vaccination Programs 
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especially one for adolescent vaccination programs.
The following narrative provides perspective on the
relative importance of different data sources in evaluat-
ing each hepatitis B vaccination activity. 
Program to prevent perinatal HBV infection
In 1990, federal funding became available to sup-
port programs to prevent perinatal HBV transmission
in the United States. Considerable efforts have been
made on program implementation; however, measur-
ing the effectiveness of perinatal program activities has
been challenging. 
Coverage surveys: To assess the effectiveness of cur-
rent activities, disease reduction goals have been estab-
lished to evaluate key programmatic elements
including; hepatitis B surface antigen (HBsAg) screen-
ing of pregnant women, immunoprophylaxis (hepatitis
B immune globulin (HBIG) and vaccine) at birth, and
completion of the vaccine series by 6-8 months of age
(Table 1). These goals have been established to ensure
that> 80% of perinatal HBV infections are prevented. 
In March 1995, the Hepatitis Branch, CDC, con-
ducted a survey of hepatitis B program coordinators to
measure progress in reaching these goals. The results
of this survey revealed that 12 states had laws or regu-
lations requiring HBsAg screening of pregnant women.
Overall, 52 program coordinators provided data on the
prevalence of HBsAg screening. For women who re-
ceived services in the public sector, most projects (60%)
reported that >90% of pregnant women were screened;
however, 20% of the program managers did not know
what percentage of pregnant women were screened
(Table 3). For women who received services in the pri-
vate sector, 28% of projects reported that >90% of preg-
nant women were screened and >50% of the projects
did not know what percentage of pregnant women
were screened. 
The birth of infants to HBsAg-positive women is the
critical surveillance event in the perinatal program and
reporting of these births is the major indicator of pro-
gram effectiveness. To evaluate reporting, the Hepatitis
Branch has provided projects with estimates on the
number of births to HBsAg-positive women that occur
each year in the United States (Table 3). These figures
are based on natality data and the estimated preva-
lence of chronic HBV infection among pregnant
women by race and ethnicity. Specifically, the esti-
mates are derived by using the following race/ethnic-
ity- specific rates of HBsAg positivity: whites = 0.13%;
blacks = 0.5%; Hispanics = 0.12%; Asian, U.S.-born =
1.6%; Asian, foreign-born = 8.9%; other = 0.5%. Based
on natality data, an estimated 20,000 infants are born to
HBsAg-positive women each year in the United States. 
The prevalence figures used to calculate the number
of births to HBsAg-positive women are derived from
the National Health and Nutrition Examination Survey
(NHANES III). NHANES III is a population-based sero-
prevalence survey which includes approximately
21,000 people nationwide. NHANES III has a limited
capacity to provide estimates on the number of HBsAg-
positive births in each state. There are several reasons
for this. NHANES has a limited sample size and the
prevalence of HBsAg among women of childbearing
age is low, thus, the confidence limits around the
NHANES estimates are wide. In addition, NHANES
cannot provide estimates on the prevalence of HBsAg
for foreign-born Asian women (there are too few in the
survey). These estimates are derived from the medical
literature (1-5). Finally, it is likely there is considerable
variability in the prevalence of HBsAg-positive women
by race and ethnicity in different parts of the country. 
Considering these limitations, CDC has calculated a
“lower confidence limit” on the number of HBsAg-
positive births that are expected to occur in each state.
These calculations are derived using the standard error
of the NHANES data and state-specific natality data.
To evaluate reporting, projects can compare the total
number of HBsAg-positive births identified each year
to the number that are expected to occur based on
natality data. 
Table 3 shows that 7,500 HBsAg-positive births
were identified in 1993 and that most projects reported
approximately 20%-40% of the expected number of
HBsAg-positive births. The rates of immunoprophy-
laxis for these infants are consistent with the national
goals and provide a measure of the number of peri-
Data Source
Program/Age-group Coverage Surveys Serologic Surveys Disease Surveillance *
Prevention of Perinatal Infection +++ +/- +
Routine Infant Vaccination +++ +++ +/-
Risk Group Vaccination under VFC
Children of immigrant mothers + +++ +
Adolescents (i.e., STD clinics, drug treatment) +++ + +++
Vaccination of Adolescents at 11-12 years of age + + +++
*This level of utility would be achieved only with addition of a special category for perinatal infection and if infants are tested and
 infections reported.




























Alabama >95 U 205 98 107 0.52 107 0.93 0.93
Alaska U 90-95 132 93 NA NA NA NA NA
American Samoa 90-95 U 132 114 79 0.60 79 1.00 0.51
Arizona <85 >95 192 105 30 0.16 0 NA NA
Arkansas >95 U 97 44 41 0.42 31 1.00 1.00
California >95 >95 5508 4365 1872 0.34 1884 1.00 0.89
CNMI 85-89 90-95 147 130 80 0.54 80 NA NA
Colorado <80 <80 171 103 57 0.33 57 0.97 0.64
Connecticut 90-95 90-95 171 102 92 0.54 85 0.74 0.51
Delaware 95 U 43 24 11 0.26 11 0.82 0.36
Florida 100 U 636 344 272 0.42 272 0.98 0.77
Georgia U U 447 246 95 0.21 95 0.75 0.52
Hawaii >95 >95 502 393 251 0.50 251 0.99 0.92
Idaho NA NA 33 15 NA NA NA NA NA
Illinois 90-95 90-95 852 537 25 0.03 14 1.00 0.86
Indiana <80 U 196 87 26 0.13 11 1.00 0.82
Iowa <80 U 102 56 18 0.18 18 1.00 0.56
Kansas U U 119 69 29 0.24 20 0.75 0.75
Kentucky 90-95 90-95 116 49 12 0.10 12 0.92 0.75
Louisiana >95 U 290 152 398 1.38 338 0.91 0.49
Maine U 80-89 33 15 12 0.36 12 1.00 1.00
Maryland >95 U 416 267 146 0.35 146 0.99 0.68
Massachusetts >95 U 415 285 208 0.50 208 0.89 0.57
Michigan 85-89 U 461 235 268 0.58 268 1.00 0.76
Minnesota U NA 292 197 213 0.73 213 1.00 0.78
Mississippi >95 U 165 80 105 0.64 103 1.00 0.87
Missouri 100 U 226 113 17 0.08 17 0.88 0.76
Montana NA NA 26 11 NA NA NA NA NA
Nebraska U U 61 31 4 0.07 4 0.75 1.00
Nevada <80 U 99 66 52 0.53 52 0.96 1.23
New Hampshire >95 >95 32 14 7 0.22 7 1.00 NA
New Jersey >95 U 619 419 1 0.00 1 1.00 1.00
New Mexico 90-95 U 72 37 35 0.49 35 NA NA
New York >95 >95 516 300 357 0.69 357 0.99 0.82
New York City >95 >95 1205 912 1149 0.95 1149 0.98 0.78
North Carolina 90-95 U 352 180 67 0.19 0 NA NA
North Dakota <80 <80 21 10 3 0.14 3 1.00 0.33
Ohio >95 U 443 213 135 0.30 109 1.00 0.87
Oklahoma <80 U 154 83 14 0.09 14 1.00 0.43
Oregon >95 U 160 104 84 0.53 84 0.99 0.46
Palau >95 U 35 NA 50 1.43 50 0.94 0.9
Pennsylvania <80 U 559 316 151 0.27 151 0.47 0.37
Puerto Rico NA NA 77 29 48 0.62 39 0.69 NA
Rhode Island >95 85-89 64 43 45 0.70 45 0.93 0.71
South Carolina 90-95 U 201 98 44 0.22 22 NA NA
South Dakota NA NA 26 11 NA NA NA NA NA
Tennessee U U 218 104 131 0.60 115 0.99 0.93
Texas <80 <80 1141 711 521 0.46 444 0.91 0.72
Utah 90-95 <80 109 65 28 0.26 28 1.00 0.89
Vermont >95 >95 15 6 0 0.00 NA NA NA
Virginia U U 460 293 67 0.15 67 0.99 0.72
Washington U U 433 309 200 0.46 203 0.99 0.29
Washington D.C 90-95 80-84 71 40 95 1.34 49 0.55 0.45
W. Virginia U U 40 15 3 0.08 3 0.67 0.67
Wisconsin 90-95 90-95 272 170 138 0.51 135 0.93 0.9
Wyoming NA NA 14 6 NA NA NA NA NA
U.S. 19155 12914 7627 0.40 7498 0.83 0.75
U = Unknown
NA = Not available
Table 3. Survey of hepatitis B program managers, March 1995, Vaccination and completion rates of inf ants
born to HBsAg+ women in 1993
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natal HBV infections prevented with a high degree of
certainty. 
There are several reasons why projects did not iden-
tify the majority of HBsAg-positive births in the United
States including: 1) at the time of the survey, many pro-
gram coordinators did not track pregnant women who
received services from private providers; 2) several
states were just implementing perinatal programs in
1993, and; 3) there may be considerable variation in the
prevalence of chronic HBV infection among different
ethnic groups by state. For example, a state with a
large number of births to foreign-born Asian women
from Japan (where the HBsAg prevalence is 2%) may
report a much lower number of HBsAg-positive births
than a state with a high percentage of births to women
from Southeast Asia (where HBsAg prevalence is 10%).
In addition, there may be variability in the prevalence
of HBsAg among women of other ethnic/racial groups
in different parts of the country. For example, a study
from New York state suggests that the prevalence of
HBsAg among white women in New York is 0.07% (ap-
proximately half the prevalence that has been observed
in NHANES) (6). 
 Population-based serological surveys: NHANES
has been used to determine the prevalence of HBV in-
fection in the U.S. In NHANES II (1976-1980), children
as young as 6 months of age were tested, while in
NHANES III (1989-1992) 6-year-olds were the young-
est age-group tested. Because the prevalence of HBV in-
fection is low among 1- to 2-year-old children and the
sample size of NHANES is limited, future NHANES
surveys will not provide a reliable measure of perinatal
program effectiveness. 
Surveillance for acute hepatitis B: Given the natu-
ral history of perinatal HBV infection, few sympto-
matic cases would be expected to be reported to
NNDSS. Over the past 10 years, approximately 300 chil-
dren 5 years of age were reported annually; however,
only 10% of these cases were reported to the Viral
Hepatitis Surveillance Program (VHSP). The lack of
epidemiologic data makes it difficult to interpret dis-
ease trends in this age-group (see Table4).
However, surveillance for perinatal HBV infection
could become a part of the VHSP. Postvaccination test-
ing of infants born to HBsAg-positive mothers pro-
vides “sentinel surveillance” for the effectiveness of the
program. Review of the immunization history of in-
fants found to be HBsAg positive provides ongoing
quality control of the program with respect to “on time
vaccination”. CSTE has changed the case definition of
acute HBV infection to include perinatal HBV infec-
tions.
Routine infant vaccination 
Vaccination coverage data combined with serologic
surveys will provide the best indicator of program
effectiveness.
Coverage surveys: Hepatitis B vaccination coverage
has been included in the National Immunization Sur-
vey conducted by the National Immunization Pro-
gram. The dose-specific ratio of
diphtheria-tetanus-pertussis (DTP) to hepatitis B vac-
cine delivered can be determined for state immuniza-
tion projects and selected immunization projects that
are IAP grantees. Provider-based assessments can pro-
vide hepatitis B vaccination coverage by practice type
and provider specialty. Infant hepatitis B vaccination
coverage data should be used to ensure high coverage
in ethnically defined populations with high rates of
early childhood HBV infection. 
      Age Group
< 5 yr 5-10 11-19
Year NNDSS* VHSP†§ VHSP/NNDSS NNDSS VHSP VHSP/NNDSS NNDSS VHSP VHSP/NNDSS
% % %
1983 312 90 29 147 78 53 2374  950 40
1984 228 69 30 141 56 40 2603  953 37
1985 273 61 22 149 45 30 2498 1100 44
1986 279 71 25 140 52 37 2552 1099 43
1987 435 47 11 181 57 32 2388  987 41
1988 353 48 14 144 54 38 1978  935 47
1989 322 56 17 151 71 47 2143  966 45
1990 316 30 10 141 30 21 1879  560 30
1991 220 23 11 130 27 21 1594  491 31
1992 228 26 11 106 24 23 1398  413 30
1993 133 12  9 114 24 27  983  377 38
* National Notifiable Diseases Surveillance System
† Viral Hepatitis Surveillance System
§ Meeting case definition
Table 4. Cases of hepatitis B in children and adolescents reported to CDC surveillance systems, 1983 -93
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Population-based serological surveys: Because few
children with acute HBV infection develop
symptomatic disease, serologic surveillance provides
the best measure of program effectiveness in
preventing early childhood HBV infection. In
NHANES II, serologic testing of children 6 months to 5
years of age detected a low prevalence of HBV infec-
tion in blacks and whites (1.29% and 0.33%, respec-
tively), but among Asian children born in the US, the
rate of infection was 6.3%. While the prevalence of
HBV infection may be too low to detect an important
difference in the prevalence of HBV infection among
blacks and whites, a reduction in the prevalence of
HBV infection among Asian children should be de-
tected in NHANES IV. In addition, special serologic
surveys in populations with previously defined high
rates of early childhood HBV infection (i.e., Alaskan Es-
kimos, Pacific Islanders, Hawaiian school children) will
continue to confirm the long-term effectiveness of rou-
tine infant vaccination (7-10).
Surveillance for acute hepatitis B: Given the natu-
ral history of early childhood HBV infection, few symp-
tomatic cases would be expected to be reported to
NNDSS. Over the past 10 years, fewer than 500 chil-
dren <10 years of age have been reported annually.
Only 20% of these cases are reported to the VHSP, and
the lack of epidemiologic data makes it difficult to in-
terpret disease trends in this age-group (Table4). Over-
all, it is strongly encouraged that all cases of hepatitis B
in children be reported using the VHSP case report
form. Only after more complete reporting occurs can
the utility of disease surveillance be ascertained for
monitoring disease reduction.  
Vaccination of children of immigrant mothers 
Specific goals for “catch-up” vaccination of children
of immigrant mothers have not been established. How-
ever, serologic surveillance could be an effective means
to determine the effectiveness of vaccination in these
populations since they are not adequately represented
in surveys to determine general vaccination coverage. 
Coverage data: Special coverage surveys would be
required to monitor the level of catch-up immunization
in these populations and to estimate its effect on pre-
venting early childhood HBV infections. 
Population-based serological surveys: Data from
NHANES II and NHANES III has shown that the
prevalence of HBV infection is at least six times greater
in US-born Asian women than in blacks or whites.
Thus, sequential monitoring of age-specific HBV infec-
tion rates in the appropriate ethnic/racial groups will
provide the best measure of the effectiveness of catch-
up hepatitis B vaccination. In addition, special studies
will be used to monitor catch-up vaccination efforts for
children living in Asian/Pacific Islander communities
(10). 
Surveillance for acute hepatitis B: Current re-
ported cases of hepatitis B in children 10 years of age
do not reliably reflect the rate of HBV infection in this
age-group. All cases of hepatitis B in children should
be reported to NNDSS and VHSP. Once more complete
reporting occurs, the utility of disease surveillance for
monitoring disease reduction can be ascertained for
this age-group. However, the disproportionately high
rate of reported disease for Asian children can be used
as an indicator of the effectiveness of this catch-up im-
munization effort (Table 5).
Age-group (years)
<5 5-10 11-19
Race/ethnicity No. % No. % No. %
White, non-Hispanic 235 (47) 231 (47) 4981 (60)
Black, non-Hispanic 152 (30) 135 (28) 2309 (28)
Hispanic  27 ( 5)  40 ( 8)  553 ( 7)
Asian/Pacific Islander  85 (17)  75 (15)  250 ( 3)
American Indian/Alaska Native   5 ( 1)  9 ( 2)  126 ( 2)
Source of Infection (mutually exclusive groups)
Transfusion/blood product  18 (  4)  17 ( 4)   72 (0.9)
Dialysis   2 (0.4)   0    6 (0.1)
Non-sexual contact of confirmed case 212 ( 46) 120 (27) 1141 ( 14)
Sexual contact/multiple partners   0   0  460 (  6)
Homosexual contact   0   0  262 (  3)
Injection drug use   0   0  885 ( 11)
Occupational exposure   0   0  131 (  2)
Other percutaneous exposure   1 (0.2)   0   11 (0.1)
Unknown 224 ( 49) 315 (70) 5314 ( 64)




Specific disease reduction goals for the vaccination
of adolescents have not been established. However, be-
cause most HBV infections in this group are sympto-
matic, specific disease surveillance and vaccination
coverage will be the best means to monitor the effec-
tiveness of adolescent hepatitis B vaccination.
Coverage data: At a meeting of hepatitis B program
coordinators in Atlanta, a tentative goal for vaccination
of adolescents was established. The group suggested
that 70% of 14 year old children (or whatever cohort is
measured) should have received 3 doses of hepatitis B
vaccine by the year 2000. Beginning in 1996, the Na-
tional Health Interview Survey will provide vaccina-
tion coverage data on a national sample of adolescents.
This data will be extremely useful in measuring pro-
gress in achieving comprehensive vaccination coverage
in adolescents for a number of vaccine antigens includ-
ing hepatitis B. 
Vaccination coverage data obtained in other settings
serving high risk adolescents (i.e., clinics for sexually
transmitted diseases, drug treatment centers) is needed
to determine the degree to which these groups have
been vaccinated against HBV. However, this surveil-
lance method is not expected to reliably predict or
monitor disease reduction. 
Population-based serological surveys: Data from
NHANES II and NHANES III has shown that the age-
specific prevalence of HBV infection increases signifi-
cantly among teenagers. While it is not known the
degree to which adolescent vaccination will lower the
prevalence of HBV infection, it is not clear at this time
whether seroprevalence data will provide a useful indi-
cator of disease reduction. 
Surveillance for acute hepatitis B: Surveillance for
acute hepatitis B is possibly the best means of monitor-
ing the effectiveness of any aspect of adolescent immu-
nization since a large proportion of HBV infections in
this age-group are symptomatic. In contrast to adults,
the male-to-female ratio in this age-group is almost
equal and suggests the greater importance of sexually
transmitted infections. While approximately 1,500
cases of hepatitis B in this age-group have been re-
ported to the NNDSS annually over the past 10 years,
only 30% were reported to VHSP. It is strongly encour-
aged that all cases of hepatitis B in teenagers be re-
ported using the VHSP case report form. Only after
more complete reporting occurs can the utility of dis-
ease surveillance be ascertained for monitoring disease
reduction.  Since program implementation, hepatitis B
vaccination coverage has increased rapidly and was es-
timated to be 58% for 19-24 month old children in the
4th quarter of 1994.
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Trends Based on Reporting to the National Notifiable
Diseases Surveillance System, 1993
From 1992 to 1993, the National Notifiable Diseases
Surveillance System (NNDSS) reported an overall re-
duction of 7% in the reported incidence rate for all
types of viral hepatitis combined (Table 1 and Figure
1), and the total case count was at its lowest level in 26
years. Although total cases of hepatitis A actually in-
creased modestly, there were substantial decreases in
the total case counts for hepatitis B (down 17% from
1992) and hepatitis C / non-A, non-B (NANB) hepatitis
(down 20%). The increase in reported cases of hepatitis
C/NANB hepatitis for the years 1990 through 1992 ap-
peared to be largely due to the reporting of anti-HCV-
positive persons identified by routine screening who
did not have acute hepatitis. This increase was not ob-
served in 1993. 
Types of Hepatitis
Hepatitis A Hepatitis B Non-A, Non-B Unspecified Total
Year No. Rate* No. Rate No. Rate No. Rate No. Rate
1966 32,859 16.77  1,497 0.79 † † § § 34,356 17.56
1967 38,909 19.67  2,458 1.28 † † § § 41,367 20.95
1968 45,893 22.96  4,829 2.49
† † § § 50,722 25.45
1969 48,416 23.98  5,909 3.02 † † § § 54,325 27.00
1970 56,797 27.87  8,310 4.08 † † § § 65,107 31.95
1971 59,606 28.90  9,556 4.74 † † § § 69,162 33.64
1972 54,074 25.97  9,402 4.52
† † § § 63,476 30.49
1973 50,749 24.18  8,451 4.03 † † § § 59,200 28.21
1974 40,358 19.54 10,631 5.15 † †  8,351 3.95 59,340 28.07
1975 35,855 16.82 13,121 6.30 † †  7,158 3.44 56,134 26.34
1976 33,288 15.51 14,973 7.14 † †  7,488 3.57 55,749 25.97
1977 31,153 14.40 16,831 7.78
† †  8,639 3.99 56,623 26.17
1978 29,500 13.53 15,016 6.89 † †  8,776 4.02 53,292 24.44
1979 30,407 13.82 15,452 7.02 † † 10,524 4.79 56,393 25.62
1980 29,087 12.84 19,015 8.39
† † 11,894 5.25 59,996 26.49
1981 25,802 11.25 21,152 9.22 † † 10,975 4.79 57,929 25.26
1982 23,403 10.11 22,177 9.58 2,629 1.14 8,564 3.40 56,773 24.52
1983 21,532 9.20 24,318 10.39 3,470 1.48 7,149 3.05 56,469 24.12
1984 22,040 9.33 26,115 11.06 3,871 1.64 5,531 2.34 57,557 24.37
1985 23,257 10.04 26,654 11.51 4,192 1.81 5,530 2.39 59,633 25.76
1986 23,430 10.02 26,107 11.17 3,634 1.55 3,940 1.69 57,111 24.43
1987 25,280 10.39 25,916 10.65 2,999 1.23 3,102 1.27 57,297 23.54
1988 28,507 11.59 23,177 9.42 2,619 1.07 2,470 1.00 56,773 23.10
1989 35,821 14.43 23,419 9.43 2,529 1.02 2,306 0.93 64,075 25.81
1990 31,441 12.64 21,102 8.48 2,553 1.03 1,671 0.67 56,767 22.81
1991 24,378 9.67 18,003 7.14 3,582 1.42 1,260 0.50 47,223 18.73
1992 23,112 9.06 16,126 6.32 6,010 2.36 884 0.35 46,132 18.09
1993 24,238 9.39 13,361 5.18 4,786 1.86 627 0.24 43,012 16.68
* Rate per 100,000 population
† Not reported until 1982
§ Not reported until 1974
Table 1. Reported Cases of Viral Hepatitis, by Type and Year, United States, 1966-93
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Hepatitis A 
The most recent peak in the inci-
dence of hepatitis A occurred in
1989, when almost 36,000 cases
were reported to the NNDSS (Ta-
ble 1). As in previous years when
epidemics of hepatitis A swept the
nation, the peak in 1989 was fol-
lowed by rapid reductions in re-
ported case levels. In 1993, the case
count began increasing again, up
5% over the 1992 level. Although
peaks in incidence of hepatitis A ex-
hibited a 7- to 10-year recurrent pat-
tern during 1954-1971, a
subsequent peak (albeit much
smaller) was not observed until
1989 (Figure 1). Data from outbreak
investigations conducted as early
as 1983 in Oregon (1) and from
1986 through 1987 in other areas of
the country indicated that injection drug users were in-
volved in an increasing number of outbreaks (2,3). Al-
though the number of hepatitis A cases associated with
injection drug use peaked in 1989, contact with another
hepatitis patient and day-care attendance continued to
be the most frequent risk factors reported. 
Trends in hepatitis A varied by region (Figure 2). In
the West, the incidence of hepatitis A reached a peak in
1989 and the increase observed nationwide during
1992-1993 has primarily been focused in this region.
The Southeast had a slight increase in incidence in
1993. In the Northeast, the incidence continued declin-
ing in 1993, and in the Midwest, hepatitis A incidence
reached a peak in 1992 and declined in 1993. 
 Analysis of risk factors from the Viral Hepatitis Sur-
veillance Program (VHSP) suggests that cases resulting
from person-to-person contact reached their highest
levels for all regions in 1989. In that year, the western
states reported proportionately more cases attributable
to day-care-related exposures and foodborne outbreaks
than did other regions. In general, however, the re-
gions did not differ substantially with respect to the
distribution of risk factors. 
Incidence rates for hepatitis A in 1993 were plotted
by county for the United States (Figure 3A). The West
Figure 1. Viral Hepatitis by Year, United States, 1952-93
For 1985 and 1986, excludes cases from New York; data not available
Source: MMWR
Figure 2. Reported cases of hepatitis A and B, by region, United States, 1975-93
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Figure 3A. Reported Cases of Hepatitis A per 100,000 Population, United States, 1993
Source: MMWR
Rate per 100,000 No cases 4.0 - < 8.0














had the highest proportion of coun-
ties with moderate-to-high rates of
hepatitis A (8 to 12 or more cases
per 100,000 population). High rates
of hepatitis A were observed in a
moderate number of counties in
the Midwest (west north-central
and east north-central regions) and
a smaller number of counties in the
south Atlantic, east south-central,
and west south-central regions. In
the West the higher incidence rates
were closely correlated with demo-
graphic factors, e.g., counties with
10% or more of the population clas-
sified as American Indian had aver-
age rates 3.5 times higher than
counties with less than 10% of the
population so classified. Similarly,
counties with 15% or more of the
population classified as Hispanic had average rates 2.1
times higher than counties with less than 15% of the
population so classified (2). County-specific rates re-
quire care in interpretation since counties in the West
are much larger and not as numerous as counties in the
Midwest and East. Population density must also be
taken into account when comparing regional rates to
ensure that the total case numbers of the larger western
counties are not misinterpreted. 
During 1983-1993, trends in incidence rates of hepa-
titis A were similar for all age-groups (Figure4A). How-
ever, persons 40 years old and older had rates less than
half of those for younger persons. After peaking in
1989, the incidence of hepatitis A decreased among per-
sons 15 years old and older, and then remained un-
changed since 1990. For those less than 15 years of age,
a peak occurred in 1990, and has declined since then. 
Hepatitis B 
Since 1985, the incidence rate of hepatitis B has de-
clined by 55% (Figure 1) to a level close to that re-
ported in 1975 (Figure 1 and Table 1). Some of the
increase in hepatitis B incidence during 1966-1985 was
attributable to improvements in serologic diagnosis,
and some of the decrease in incidence in recent years
may be due to changes in state reporting practices, i.e.,
the case definition published by CDC and the Council
of State and Territorial Epidemiologists in 1990 had not
been uniformly adopted by all states. As states have
adopted the CDC case definition, or changed the defini-
tion being used, large variations in reported cases of
hepatitis B have been observed from some states dur-
ing the last 3 years (4,5). State offices were contacted af-
ter they reported changes in hepatitis B incidence of
over 200% from the previous year. Each office con-
tacted confirmed that changes in their use of case defi-
nitions or changes in the reporting of confirmed vs
suspected cases accounted for the unusual increase or
decrease. 
Despite these artifacts, there has been a significant,
prolonged decline in the incidence of hepatitis B in the
United States. Thirty-eight states reported decreases,
averaging 27% over 1992-93; however, 14 states re-
ported increases in the incidence of hepatitis B from
1992 to 1993, with an average percentage increase of
19%. Regionally, hepatitis B incidence has been higher
and has shown wider variations over time in the West
than in the other regions (Figure 2). Each of the four re-
gions reported increases in incidence until the mid-
1980s. By 1993, the rate in each region had declined,
with the Southeast having the highest rate and the
Northeast the lowest. As shown in Figure 2, the inci-
dence rates for all of the regions have become more
nearly equal.
County-specific incidence rates for hepatitis B dem-
onstrate the sporadic distribution of cases in the United
States (Figure 3B). High rate counties can be found in
each region and with few exceptions in each state.
Comparison of county rates should take into account
population density as well as geographic size. 
Age-specific incidence rates for hepatitis B have de-
clined since 1985 (Figure 4B). The highest rates by age
were among 15- to 24-year-olds until 1987, and among
25- to 39-year-olds from 1987 to the present. Although
rates have dropped by 50% for these two age-groups
since 1985, they have remained relatively stable for per-
sons aged 40 and older during this period. In 1993,
rates among 0- to 14-year-olds dropped by less than
4%.
Figure 4A. Reported Cases of Hepatitis A, by Age, United States, 1983-93*
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Figure 3B. Reported Cases of Hepatitis B per 100,000 Population, United States, 1993
Source: MMWR
Rate per 100,000 No cases 4.0 - < 8.0














Non-A, Non-B Hepatitis  
In 1989, the NNDSS reported an incidence rate of
1.02 cases of NANB hepatitis per 100,000 population.
From 1990 through 1992, the NNDSS reported that the
incidence of NANB hepatitis more than doubled (Table
1). In 1993, the rate dropped by 21% to 1.86 cases per
100,000. This decline is consistent with trends observed
in the Sentinel Counties study, where the incidence
rate of reported NANB hepatitis has declined by 80%
since 1989. This discrepancy between the two surveil-
lance systems can be attributed to an artifactual in-
crease in the number of cases reported to NNDSS as a
result of persons being screened by blood banks and
others for antibody to the hepatitis C virus (anti-HCV).
In some states, laboratory reports of anti-HCV positiv-
ity in the absence of confirmation of acute clinical dis-
ease are accepted as case reports of NANB hepatitis,
leading to the artifactual changes in the reported inci-
dence of this disease. Persons who may test positive for
anti-HCV include not only those with acute sympto-
matic hepatitis C, but also persons with past and
chronic HCV infections, and persons with no viral
hepatitis infections (false positives).
For all cases of suspected viral hepatitis, CDC rec-
ommends 1) using case definitions agreed upon by the
Council of State and Territorial Epidemiologists and
CDC, 2) diagnosing cases on the basis of both clinical
and serologic evidence, and 3) reporting only serologi-
cally confirmed cases to CDC, including hepatitis
C/NANB hepatitis diagnosed by exclusion of hepatitis
A and B. 
In April 1995, the NNDSS changed the category
heading for viral hepatitis in Table II of the MMWR to
reflect these reporting changes. Cases reported as hepa-
titis C or as hepatitis NANB are now combined in Ta-
ble II as hepatitis C/NANB. Some patients with
hepatitis C may continue to present as NANB cases,
since an average of 20% of patients with acute hepatitis
C will not have developed anti-HCV (as determined by
the second-generation enzyme immunoassay by 5 to 6
weeks after onset of their hepatitis (6,7). In addition,
these tests may not detect any anti-HCV in approxi-
mately 10% of patients infected with HCV, or anti-
HCV testing may not have been performed. 
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Viral Hepatitis Surveillance Program, 1993
The total numbers of cases reported to the Viral
Hepatitis Surveillance Program (VHSP) are shown in
Table 1A. Approximately 36% of hepatitis A cases, 26%
of hepatitis B cases, and 18% of NANB hepatitis cases
reported to the NNDSS in 1993 were also reported to
the VHSP. These percentages reflect a substantial de-
cline in reporting to the VHSP. Reporting to the VHSP
remains inconsistent among states, with increasing
numbers of states reporting fewer of their NNDSS
cases to the VHSP than in previous years (Table 1B). In
1987, six states reported to VHSP less than 15% of their
NNDSS cases; in 1993, this trend increased to 12 states.
The agreement between reporting to the NNDSS
and to the VHSP does not necessarily measure the com-
pleteness of reporting from a particular state, since not
all cases may be reported to the NNDSS and the two
systems have different reporting criteria. The increas-
ing discrepancy between the two systems has resulted
in differences in the relative proportions of types of vi-
ral hepatitis reported. Before 1990, the proportions of
reported cases by type were similar between the two
surveillance systems. Since then, the proportion of
hepatitis cases reported as hepatitis A to the two sys-
tems have remained similar, but the proportion of
cases reported as hepatitis B have been discrepant: 24%
to 27% of the total VHSP cases were reported as hepati-
tis B, compared with 35% to 38% of total cases reported
to NNDSS. The VHSP also received reports on smaller
proportions of the total number of NANB hepatitis
cases (7% to 8% of total cases) than did NNDSS (up to
13% of total cases).
These differences in proportions of cases are partly
due to the fact that VHSP excludes cases that do not
meet the case definition (VHSP eliminated 15% of re-
ported cases as noncases in 1993). In addition, because
of strict adherence to the case definition, VHSP classi-
fied a larger proportion of reported cases as nonspe-
cific hepatitis: 15% of cases were classified as hepatitis
unspecified by the VHSP during 1993 compared with
1.5% of cases reported to NNDSS. Beginning with data
collected in 1995, hepatitis cases that have type unspeci-
fied are no longer requested or printed in the MMWR. 
 The VHSP excludes reported cases that do not meet
the case definition for acute viral hepatitis (see “Case
Definition” section, page 22 ), including cases that
seem to be due to chronic infections. Some responses to
the VHSP questionnaires are incomplete, and the infor-
mation is insufficient to verify the case as an acute in-
fection, or to confirm the serologic type of hepatitis,
even though partial testing may have been done. Cases
may also be reported too late to be included in the
analysis. The latest date for submitting case reports to




Reports submitted on Form CDC 53.1 Rev. 8-89 (new form) 18,064 16,433 13,563
Reports submitted on Form CDC 53.1 Rev. 8-84 (old form) 1,772 884 617
Reports submitted electronically as extended NETSS* records 810 961 1,427
Total cases reports submitted to VHSP 20,646 18,278 15,607
Total cases serologically confirmed 19,014 16,916 14,469
Total cases meeting case definition for acute hepatitis 17,094 15,362 13,199
Symptomatic hepatitis A 9,621 9,735 8,643
Symptomatic hepatitis B 5,771 4,411 3,526
Hepatitis A and B co-infection 237 151 174
Symptomatic non-A, non-B hepatitis 1,465 1,065 856
Total cases reported to NNDSS† 47,223 46,132 43,012
Hepatitis A 24,378 23,112 24,238
Hepatitis B 18,003 16,126 13,361
Hepatitis non-A, non-B 3,5822 6,010 4,786
Hepatitis, unspecified 1,260 884 627
* National Electronic Telecommunications System for Surveillance
† National Notifiable Diseases Surveillance System
Table 1A. Cases Reported to Viral Hepatitis Surveillance Program Compared with NNDSS, by Type of S ubmission, 1991-93
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Case Definition
Epidemiologic data about reported cases of acute vi-
ral hepatitis are essential for defining the groups at risk
and for monitoring changes in such groups. Since new
disease acquisition is the event of interest, chronic infec-
tions should not be reported.
In 1990 the VHSP updated the case definition for
acute viral hepatitis to include IgM anti-HBc for im-
proved diagnosis of acute hepatitis B, to clarify the re-
porting of NANB hepatitis, and to include delta
hepatitis as a separate diagnostic category. The clinical
criteria remain the same: an acute case must include an
illness with discrete date of onset, and jaundice or ele-
vated serum aminotransferase levels greater than 2.5
times the upper limit of normal. The serologic criteria
used to distinguish the different types of hepatitis were
as follows: hepatitis A is defined as IgM anti-HAV-posi-
tive (regardless of HBsAg status); hepatitis B as IgM
anti-HBc-positive (if done) or HBsAg-positive and IgM
anti-HAV-negative (if done); and NANB hepatitis as
IgM anti-HAV-negative, and IgM anti-HBc-negative (if
done) or HBsAg-negative. Although by 1993 only 55%
of reported cases were tested for both hepatitis A and
B, 87% had sufficient serologic testing to designate a
specific type. Only those patients with a specific sero-
logic diagnosis are included in the following analyses.
Cases are excluded if they do not satisfy the criteria
for acute viral hepatitis. Among serologically con-
firmed cases in 1993, 6% of hepatitis A cases, 13% of
hepatitis B cases, and 9% of NANB hepatitis cases were
excluded because they failed to meet the case crite-
ria. Compared with hepatitis B patients who ful-
filled the criteria for acute hepatitis, more persons
with hepatitis B who were asymptomatic or had no
date of onset were 14 years of age, were Asian/Pa-
cific Islander, were dialysis patients, or had histo-
ries of blood transfusions or surgery. 
Except for age, NANB hepatitis patients not
meeting the case definition showed a similar pat-
tern. Compared with NANB hepatitis patients who
fulfilled the criteria for acute hepatitis, more per-
sons with NANB hepatitis who were asympto-
matic or had no date of onset were 40 years of
age, were patients undergoing dialysis, or had his-
tories of surgery. This pattern, as well as that for
hepatitis B, is consistent with that for the earlier
years. For both hepatitis B and NANB hepatitis,
these findings suggest that these persons may have
been routinely screened for HBsAg or for antibody
to the hepatitis C virus (anti-HCV), and found to
be positive without any evidence of acute illness. 
Hepatitis A and B coinfections were examined
in the 1993 data, and constituted approximately 1%
of cases meeting the case definition. These cases
displayed no specific clustering or associations
with geographic or demographic factors. For pur-
poses of risk factor analysis, these cases were
counted twice, and included as hepatitis A cases
and hepatitis B cases.
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Table 1B. Proportion of NNDSS-Reported Cases Reported to VHSP by States, 1993
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Use of Serologic Tests
for Diagnosis
Serologic testing for the diagno-
sis of hepatitis, beginning with
hepatitis B surface antigen
(HBsAg) in 1972, immunoglobulin-
M antibody to hepatitis A virus
(IgM anti-HAV) in 1981, and IgM
antibody to hepatitis B core antigen
(IgM anti-HBc) in 1984, has been
critical in distinguishing the types
of viral hepatitis. Serologic testing
for any marker using one or more
tests has increased from 60% in
1983 to 94% in 1993 (Figure 1). By
1993, only 6% of reported cases
were diagnosed on the basis of the
HBsAg test alone. However, there
has been a decline in the number of cases reported in
which testing for both hepatitis A and hepatitis B was
done. In 1989, 76% of physicians reported using tests
for both types (the highest percentage reached); this de-
clined to 70% in 1990, 68% in 1991, 63% in 1992, and to
55% in 1993. At the same time, the number of cases re-
ported in which testing only for hepatitis A was done
increased over this period, from 15% in 1989 to 28% in
1993. The reliance on testing for hepatitis A alone for
these cases may be related to the higher incidence of
hepatitis A in communitywide outbreaks since 1989. 
Demographic Characteristics
Among persons less than 15 years of age, hepatitis
A remained the most frequent of the types reported;
hepatitis B and NANB hepatitis were reported in small
numbers of persons in this age-group (Table 2). The
percentage of NANB hepatitis cases among patients 60
years old and older (8.8%) was the highest of the three
types. However, most persons who acquire any type of
viral hepatitis are between the ages of 20 and 39: ap-
proximately 45% of hepatitis A, 63% of hepatitis B, and
61% of NANB hepatitis are reported among persons in
this age span.
From 1992 to 1993, the number of hepatitis A cases
among patients 20-39 years of age decreased 10%; hepa-
titis B cases, 21%; and NANB hepatitis cases, 19%.
Demographic factors for all types showed patterns con-
sistent with those of previous years (Table 2).
The male-to-female case ratios were similar to pre-
vious years: for hepatitis A, the male-to-female ratio
was 1.2:1; for hepatitis B, 1.5:1; and for NANB hepati-
tis, 1.4:1. 
Non-Hispanic whites accounted for the majority of
all types reported, including 57% of hepatitis A, 54% of
hepatitis B, and 65% of NANB hepatitis (Table 2). How-
ever, the proportion of each type of hepatitis reported
as non-Hispanic white declined. Non-Hispanic blacks
in 1993 continued to represent disproportionately
higher percentages of hepatitis B, accounting for 31%
of all hepatitis B cases. Among black patients with any
type of hepatitis, hepatitis A was the predominant type
in 1993, accounting for 55% of all cases. This represents
a shift from 1989, when 53% of all cases among blacks
were hepatitis B cases. Data from a large population-
based seroprevalence study confirm that the preva-
lence of HBV infection is more than four times higher
among blacks than among whites (1). The percentage
of blacks among NANB hepatitis patients increased
from 12% in 1989 to 22% in 1992, but decreased to 18%
in 1993. In 1989, Hispanic patients accounted for 9% of
reported hepatitis A cases. While this percentage in-
creased to 12% by 1993, the absolute number of His-
panic cases declined, as was true for other
racial/ethnic groups. When the percentages of His-
panic cases were examined for both old reporting
forms and newly revised forms for the 1990 data, there
was no evidence that the coding of ethnicity separately
from race affected reporting of such cases. 
Analysis of Risk Factor Data
The analysis of epidemiologic data for 1993 took
into consideration the changes in both incidence and re-
porting practices. Reporting was analyzed by groups
of states to determine if significant biases existed in the
data when reports from all participating states were in-
cluded for analysis. Criteria for good reporting states
(“core” states) included adequate serologic testing of
reported cases (at least 80% of reported cases tested for
IgM anti-HAV or HBsAg), and reporting to the VHSP
Figure 1. Serologic Tests to Diagnose Hepatitis, 1983-1993
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of a high proportion of cases reported to NNDSS (at
least 50% of total cases reported to NNDSS also re-
ported to VHSP). In addition, core states were further
subdivided into those with rates above the national av-
erage for each type, and those with rates below the na-
tional average, and comparisons were made between
these subgroups. Trends in these core states were then
compared to trends in the remaining states for evi-
dence of consistency and potential bias. 
For hepatitis A, analysis of the core group of states
showed that trends were very similar between the core
states and all reporting states, and between the high-
rate and low-rate subgroups. In the trend analyses that
follow, hepatitis A risk factors were based on reported
cases from all reporting states, and trends were
analyzed by using absolute numbers of cases. For hepa-
titis B and C/NANB, a core group of 15 states were se-
lected using the same reporting criteria and high levels
of serologic testing for HBV during 1983-1993. These
states accounted for approximately 30% of all cases of
hepatitis B reported to the VHSP in this period. 
For hepatitis B and C/NANB hepatitis, artifactual
changes in reporting levels resulted in significant differ-
ences between the trends for all VHSP states and the
trends in the core states, although there were no differ-
ences between high- and low-incidence states. For
hepatitis B and hepatitis C/NANB hepatitis, trends in
risk factors were analyzed by using absolute numbers
of cases from the core states only. 
Epidemiologic Characteristics
Table 3 presents crude frequencies of the potential
sources of infection reported by patients with viral
hepatitis. The same questionnaire was used for all pa-
tients with hepatitis, regardless of type. Although ques-
tions about selected risk factors associated primarily
with hepatitis A have not always been asked for
hepatitis B and NANB hepatitis, and vice versa, cases
reported in 1993 have shown an improvement in this
respect. Patients may also give a positive response to
more than one factor; therefore, the data listed in
Table3  are not mutually exclusive.
Hepatitis A
Personal contact with a hepatitis A patient contin-
ued to be the predominant source of infection among
persons with hepatitis A in 1993. The crude frequency








Characteristic No. % No. % No. %
Age (Years)
<5 456 5.2 7 0.2 14 1.6
5-9 1,066 12.1 15 0.4 9 1.1
10-14 801 9.1 63 1.7 7 0.8
15-19 778 8.8 276 7.4 38 4.4
20-29 2,207 25.0 1,265 34.1 203 23.7
30-39 1,772 20.1 1,061 28.6 316 36.9
40-49 784 8.9 569 15.3 131 15.3
50-59 385 4.4 230 6.2 54 6.3
60+ 513 5.8 195 5.3 75 8.8
Unknown 55 0.6 33 0.9 9 1.1
Sex
Male 4,742 53.8 2,179 58.7 490 57.2
Female 3,917 44.4 1,478 39.8 349 40.8
Unknown 158 1.8 57 1.5 17 2.0
Race/Ethnicity
White, non-Hispanic 4,980 56.5 2,010 54.1 553 64.6
Black, non-Hispanic 1,579 17.9 1,140 30.7 155 18.1
Hispanic 1,072 12.2 202 5.4 57 6.7
American Indian or Alaskan Native 385 4.4 51 1.4 24 2.8
Asian or Pacific Islander 186 2.1 76 2.0 17 2.0
Unknown 615 7.0 235 6.3 50 5.8
Source: Viral Hepatitis Surveillance Program
Table 2. Distribution of Viral Hepatitis Types A, B, and Non-A, Non-B, by Age, Sex, and Ethic Grou p, United States, 1993.
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similar to the rates in previous years. Many persons re-
ported two or more potential sources of infection. Of
those patients who were associated with day-care cen-
ters, 41% also reported personal contact with a hepati-
tis A patient, and 7% were part of a suspected
foodborne or waterborne outbreak. Of those reporting
contact with a hepatitis A patient, 6% also reported be-
ing part of a suspected foodborne or waterborne out-
break.
 Since hepatitis A has an average incubation period
of 30 days and is transmitted by the fecal-oral route,
the characteristics reported by persons with hepatitis A
as having occurred in the 6 weeks to 6 months prior to
illness (Table 3) are generally not applicable to trans-
mission of this virus (2). Although homosexual men
are considered at increased risk of acquiring hepatitis
A (3), the frequency with which homosexual activity
was reported by persons with hepatitis A (3.6%) may
be understated, since only 46% of the patients were
asked the question in 1993. However, this percentage
has increased in recent years. The frequency with
which injection drug use was reported by patients with
hepatitis A may be more reliable than in the past, since
over 70% of patients with hepatitis A answered this
question in 1993. These improvements lend greater va-
lidity to these data than in previous years. 
Of patients reporting personal contact with a hepati-
tis A patient, 10% reported sexual, 45% reported house-
hold, and 45% reported other contact. Of those
reporting other than sexual or nonsexual household
contact, none had reported day-care-related exposures,
but 8% reported being a part of a suspected outbreak. 
To better define patterns of hepatitis A virus trans-
mission, patients who reported more than one poten-
tial source of infection were assigned to only one group
on the basis of their most probable source. These mutu-
ally exclusive groups are shown in Table 4. Contact
with another person with hepatitis A was the risk fac-
tor most frequently cited. Association with a day-care
center and international travel were the two risk fac-
tors next in importance. 
The frequency with which the various risk factors
were reported was influenced by the age of the patient.
Contact with another person with hepatitis A was the
most frequently reported risk factor for all age-groups,
although the percentage of patients reporting this risk
factor decreased with increasing age. For persons less
than 15 years old, being a child in a day-care center
was the next most frequently reported risk factor. For
those aged 15-39, contact with a day-care child or em-
ployee was the next most important risk factor. Report-










Reported within 2-6 weeks of illness*
Child/employee in day-care center 6.8 1.6 1.7
Contact of day-care child/employee 10.9 4.7 5.0
Personal contact with hepatitis A patient 33.6 1.8 3.5
Suspected foodborne or waterborne outbreak 4.7 0.3 0.6
International travel 8.4 3.2 2.4
Reported within 6 weeks to 6 months of illness*
Blood transfusion 0.4 1.0 2.4
Injection Drug use 3.7 10.5 23.0
Medical/dental employment 2.9 3.5 4.0
Hemodialysis-associated 0.9 1.2 1.5
Personal contact with B/non-A, non-B patient+ 3.8 17.7 13.2
Homosexual activity 3.6 6.9 3.5
Multiple sex partners 4.9 20.2 12.5
Dental work 11.1 15.5 16.8
Surgery 3.5 6.6 8.1
Acupuncture 0.5 0.5 0.5
Tattooing 1.8 4.3 5.7
Other percutaneous exposure 0.9 3.2 2.7
Known hepatitis B vaccine responder NA 0 NA
Ever received hepatitis B vaccine 3.4 NA 3.5
* Approximately 67% to 76% if hepatitis B patients, and 70% to 81% of NANB hepatitis patients answer ed these questions.
+ Approximately 60% to 70% of hepatitis A patients answered the non-sexual questions; 46% answered th ese regarding sexual
 preferences of number of sex partners; therefore, reported frequencies for these risk factors may b e unreliable (see text).
Table 3. Crude Frequency of Potential Sources for Acquiring Viral Hepatitis and Other Characterist ics, 1993
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dropped by 1993 to low levels (4%) for this age-group.
For persons over 40 years of age, international travel
and being a part of a suspected foodborne or water-
borne outbreak were the next most frequent risk fac-
tors. 
International travel was reported in 6% of hepatitis
A cases in 1993. South and Central America were the lo-
cations visited most frequently (67% of travel-related
cases in 1993). Destinations in Asia and the South Pa-
cific were visited next most often (10% of cases in
1993). The duration of stay was 1-3 days in 17% of
cases with international travel as a risk factor, 4-7 days
in 15%, and more than 7 days in 68%. Among patients
reporting short stays (1-3
days), over 90% reported
visits to South/Central
America. 
Race and ethnicity were
examined among hepatitis
A patients with interna-
tional travel as a risk factor.
Hispanic patients accounted
for 47%, non-Hispanic
whites accounted for 43%,
and Asian/Pacific Islanders
for 8% of cases. Non-His-
panic blacks accounted for
less than 2% of travel-re-
lated cases in 1993. There
was an association between
race and location visited:
92% of Hispanic patients
with travel-related hepatitis
A visited South/Central
America, while 75% of non-
Hispanics did so. Among
Asian/Pacific Islander patients, 85% visited
Asian/South Pacific destinations, while 0% to 7% of
other races or ethnic groups visited these locations. 
Because the total number of hepatitis A cases re-
ported has changed over the years, the absolute num-
bers of cases for each risk factor show more accurately
the trends over time for hepatitis A. The numbers of
cases associated with personal contact with another
hepatitis A patient during 1983-1993 have exhibited the
greatest variation (Figure 2), with an increase of over
100% occurring from 1983 to 1989, followed by a com-
parable decrease from 1989 to 1993. Day-care-related
cases increased more slowly during this period, but
Percentage of Patients By Age (years)
Epidemiologic Characteristics for Prior 6 weeks by
Mutually Exclusive Groups*
Total <1-14 15-39 40+
N = 8,817+ N = 2,323 N = 4,757 N = 1,682
Child/employee in day-care center 6.9 17.2 2.9 2.5
Contact of day-care child/employee 8.6 6.4 11.0 5.1
Personal contact with hepatitis A patient 22.0 29.0 21.8 12.8
Suspected food- or waterborne outbreak 2.2 1.2 2.1 3.9
International travel 6.3 8.2 5.2 6.5
Homosexual activity 4.9 0.2 6.9 3.9
Injection drug use 2.4 0.0 3.8 2.0
Unknown 46.7 37.8 46.3 63.3
Clinical characteristics
Jaundice 83.0 81.7 85.7 76.9
Hospitalized for hepatitis 18.8 10.6 19.5 29.1
Death as a result of hepatitis 1.7 0.2 2.0 3.2
* In decreasing order of exclusion.
+ Number includes age unknown.
Table 4. Epidemiologic and Clinical characteristics of Patients Reported with Hepatitis A, by Age Gr oup, United States,
1993
Figure 2. Trends in Selected Risk Factors for Patients Reported with Hepatitis A
by Mutually Exclusive Groups, United States, 1993
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peaked in 1989 also, followed by a drop of 47%. The
numbers of cases attributable to drug use increased
steadily between 1983 and 1989, and declined rapidly
to their present low level. Cases related to homosexual
activity remained at low levels from 1983 through
1987. By 1989, however, there was a 3.6-fold increase in
cases of hepatitis A among homosexual men, and out-
breaks of hepatitis A in this population subgroup were
reported. Cases among homosexual men have re-
mained at higher levels through 1993. Foreign travel
and foodborne outbreak-associated cases peaked in
1988 and declined overall since then.
 Jaundice characterized an average of 85% of the re-
ported hepatitis A cases in 1993. Although this fre-
quency was similar across age-groups, jaundice and
other symptoms are uncommon among young children
infected with hepatitis A virus. Thus, reported cases
substantially underestimate the infection burden
among the youngest age-group. The rate of hospitaliza-
tion of patients with hepatitis A has remained steady
in 1993, and continues to increase with increasing age.
The case-fatality rate for hepatitis A patients also in-
creased with age, and showed a slight increase with
time as well for those aged 15 and over in 1993.
Hepatitis B
Based on crude frequencies of reported risk factors,
contact with another hepatitis B patient, injection drug
use, and having multiple sex partners were the three
most frequently reported potential sources of infection
for hepatitis B patients in 1993 (Table 3). In 1993, hav-
ing multiple sex partners was the most frequent poten-
tial source of infection reported. Homosexual
preference was reported by 7% of hepatitis B patients
during 1993. As with other types of hepatitis, several
possible sources of infection were often reported for
the same patient. 
Seventy-two percent of the persons with hepatitis B
were asked about potential risk factors commonly asso-
ciated with hepatitis A that occurred within the 2 to 6
weeks prior to illness. Although these factors are gener-
ally not associated with the transmission of HBV be-
cause the incubation period is too short, health-care
workers interviewing patients with hepatitis are en-
couraged to obtain from each patient information on
all types of risk factors, both to detect newly emerging
problems (as occurred with injection drug use and
hepatitis A) and to ensure a complete exposure history
when cases are serologically classified. 
Events or conditions reported within the 6 months
prior to hepatitis B illness — such as history of dental
work, surgery, acupuncture, tattooing, or other percu-
taneous exposures — are not considered likely sources
of sporadic infection, but are primarily useful in identi-
fying clusters of cases at the local level.
Of three patients reported with acute hepatitis B
and evidence of having responded to the hepatitis B
vaccine, all three were also reported to have coinfec-
tions with acute hepatitis A. After follow-up with the
reporting health department, none of these cases were
found to be true candidates for breakthrough infec-
tions.
Persons who reported multiple risk factors for hepa-
titis B were assigned to mutually exclusive groups  (2,
4-6) (Table 5). As a percentage of all cases, being het-
erosexually active with multiple partners has replaced
injection drug use as the predominant risk factor for ac-
quisition of hepatitis B. Personal contact with another
hepatitis B patient was the third most common risk
factor. Of personal contacts in 1993, 68% were sexual,
and 17% were nonsexual household contacts. The re-
maining 15% of personal contacts, classified as “other”,
are unclear as to specific sources because information
Percentage of Patients By Age (years)
Epidemiologic Characteristics for Prior 6 weeks by
Mutually Exclusive Groups*
Total <1-14 15-39 40+
N = 3,714+ N = 85 N = 2,602 N = 994
Injection drug use 10.5 0.0 12.3 6.8
Homosexual activity 9.4 0.0 10.6 6.7
Employed in medical/dental field 3.1 0.0 3.0 3.7
Hemodialysis 0.4 1.2 0.2 0.7
Personal contact with hepatitis B patient 8.3 25.9 8.3 6.6
Multiple sex partners 12.2 5.9 14.4 7.1
Blood transfusion 0.8 2.6 0.3 2.0
Unknown 55.3 64.4 50.9 66.4
Clinical characteristics
Jaundice 81.5 75.0 83.4 76.9
Hospitalized for hepatitis 28.2 21.0 25.5 36.0
Death as a result of hepatitis 1.4 0.0 1.1 2.1
* In decreasing order of exclusion.
+ Number includes age unknown.
Source: Viral Hepatitis Surveillance Program
Table 5. Epidemiologic and Clinical characteristics of Patients Reported with Hepatitis B, by Age Gro up, United States, 1993
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was insufficient to determine how transmission oc-
curred. Employment in the medical or dental field,
blood transfusions, and dialysis accounted for less than
5% of cases. For those patients employed in a medical,
dental or other field involving contact with human
blood, 23% reported frequent blood contact in 1993,
down from 36% in 1992. Transfusion as a source for
HBV has remained at a low level (0.8%) because of rou-
tine screening of blood donors for HBsAg and anti-
HBc, and because of donor selection and deferral
procedures. Screening for HBsAg has been mandatory
since 1972. Smaller improvements in preventing post-
transfusion hepatitis B occurred in the mid-1980s, with
self-exclusion of high-risk donors related to the preven-
tion of human immunodeficiency virus (HIV) infection
and later anti-HBc screening. Hepatitis B among chil-
dren younger than 15 years old is associated primarily
with personal contact with another infected person.
The percentage for 1993, 26%, is somewhat higher than
the 22% reported in 1992. None of these patients re-
ported injection drug use, while 6% reported multiple
sex partners in 1993 as their primary risk factor. The
percentages of persons reporting no known source of
infection in the youngest and oldest age-groups were
similar to those reported in 1992.
To ensure that possible biases owing to artifactual
decreases in reporting were minimized, the analysis of
trends in hepatitis B risk factors for 1983 to 1993 was re-
stricted to the absolute numbers of cases reported in
the core states only. For these states during 1989-1993,
decreases occurred in the numbers of cases attributed
to injection drug use (an 83% decrease), personal con-
tact with a hepatitis B patient (73% decrease), and mul-
tiple sexual partners (35% decrease).
The trends in risk factors associated with hepatitis B
in the core states, among men and women separately,
are shown in Figures 3 and 4. Among men, injection
drug use has shown the largest change from 1983 to
1993. After an increase of 116%
from 1983 to 1989, the numbers of
cases among men attributed to in-
jection drug use decreased by
85% (Figure 3). Safer needle-using
practices, or changes in the types
of drugs used (injection to nonin-
jection) are possible reasons for
this reduction. The numbers of
cases among men attributable to
personal contact with another
hepatitis B patient has been more
stable, showing a gradual decline
from 1989 to 1993. For these male
patients, 52% to 67% of contacts
were sexual, while 13% to 20%
were household contacts. Homo-
sexual activity, the second most
commonly reported risk factor,
declined to its lowest level in
1993. Declines in the other reported risk factors —
health-care employment and blood transfusion — con-
tinued through 1993.
Risk factors for women with hepatitis B displayed
some of the same trends presented for men, with injec-
tion drug use as a risk factor increasing from 1983 to a
peak in 1989 (Figure 4), followed by a drop to pre-1983
levels. However, among women, contact with another
hepatitis B patient increased more dramatically than
among men and since 1990, was reported with a higher
frequency than injection drug use. As with men, the
majority of contacts associated with such cases have
been sexual, reaching 72% in 1993, while only 11%
have been household contacts.
The decrease in the percentage of female patients re-
porting medical and dental employment as a risk fac-
tor during 1983-1993 has been more pronounced than
that for men. This decline is most probably attributable
to immunization of health-care workers with hepatitis
B vaccine. The percentage of cases attributable to blood
transfusions has remained at low levels since 1988. The
same trends in both men and women have been ob-
served in the Sentinel Counties study(19). 
Jaundice as a clinical characteristic of hepatitis B is a
common symptom in patients over 10 years of age (Ta-
ble 5); 82% of all patients were reported with jaundice,
regardless of age. As with hepatitis A, jaundice and
other symptoms were notably less frequent for young
children, suggesting more extensive underrepresenta-
tion of this age-group among reported cases. Overall
hospitalization rates remained stable, showing little
change since 1988, but the rates of hospitalization for
patients 40 years old and older dropped slowly but
steadily, from 50% in 1985 to 36% in 1993. Death as a re-
sult of hepatitis B was reported in approximately 1% of
patients in 1993.
 Nationwide, the incidence of hepatitis B increased
by 67% from 1978 to 1985 and then declined to its low-
Figure 3. Trends in Selected Risk Factors for Patients Reported with
Hepatitis B by Mutually Exclusive Groups, Males, Selected States, 1983-93
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est incidence since 1974. Since its
original licensing in 1981, hepatitis
B vaccine has been used in increas-
ing quantities each year. However,
the role of the vaccine in the decline
of the incidence of hepatitis B varies
across risk groups. From 1985 to
1989, hepatitis B among homosex-
ual men declined more rapidly than
among other risk groups, not be-
cause of vaccine use but because of
behavioral changes resulting from
awareness of acquired immunodefi-
ciency syndrome (AIDS)(7). Hepati-
tis B also declined among
health-care workers during this pe-
riod, who were the largest users of
hepatitis B vaccine. From 1989 to
1993, hepatitis B among injection
drug users declined by 46% despite
the low levels of vaccine usage in
this risk group. Hepatitis B among heterosexuals de-
creased during this period also, possibly due to wider
use of vaccine. 
Vaccination programs and vaccine usage have been
focused primarily on three risk groups: health-care
workers who are exposed to blood, staff and residents
of institutions for the developmentally disabled, and
staff and patients in hemodialysis units (9). For health-
care and public safety workers, the Department of La-
bor in 1991 issued regulations that require employers
to offer hepatitis B vaccine to persons at occupational
risk of infection. However, the ability to immunize the
groups that account for most of the HBV infections is
severely limited for several reasons: the failure both of
health-care providers and of the target populations to
recognize the specific groups at high risk for infection;
the difficulty in identifying persons with these high-
risk behaviors before they become infected; and the dif-
ficulties in reaching these groups for the delivery of
vaccine and at the appropriate time for vaccination (7).
Adults in general, and groups such as injecting drug
users in particular, are extremely difficult to access for
delivery of vaccine (11). In addition, once persons be-
gin the lifestyles associated with a high-risk group,
they may become infected before vaccine can be given.
Thus, the major obstacles to reducing the incidence of
HBV infection in the United States have been the diffi-
culties in identifying persons before they become in-
fected and vaccinating them promptly. To overcome
these problems, the Immunization Practices Advisory
Committee recommended in 1991 a program of routine
vaccination of all infants (9). In 1995 the same commit-
tee recommended the expansion of this program to
cover 1) vaccination of all unvaccinated children aged
<15 years who are Pacific Islanders or who reside in
households of first-generation immigrants from coun-
tries where HBV is of high or intermediate endemicity;
and 2) vaccination of all 11- to 12-year-old children
who have not previously received hepatitis B vaccine
(9). 
Hepatitis C/Non-A, Non-B Hepatitis 
Based on the crude frequencies with which risk fac-
tors were reported, injection drug use was the risk fac-
tor most commonly reported by hepatitis C/NANB
patients (Table 3). Many of these persons also reported
more than one potential source of infection. Of those re-
porting contact with another person with hepatitis
C/NANB, 25% also reported injection drug use and 5%
reported employment in a medical or a dental field. Of
those reporting multiple sex partners, 35% also re-
ported injection drug use.
The behaviors commonly associated with hepatitis
A that were reported by persons with hepatitis
C/NANB to have occurred within 6 weeks of illness
are generally not applicable to the transmission of
hepatitis C/NANB (Table 3). Since transmission of
NANB hepatitis by the fecal-oral route has not been
demonstrated in this country, reporting an association
with a foodborne or a waterborne outbreak represents
misclassification of the source. 
As with hepatitis B, potential exposures associated
with dental work, surgery, acupuncture, tattooing, and
other percutaneous procedures are not judged to be
probable sources of sporadic infection (12). Hepatitis
C/NANB patients with no known source of infection
reported these exposures at rates no different from
those of the general population. 
Based on assignment to mutually exclusive catego-
ries, persons with hepatitis C/NANB reported injec-
tion drug use most frequently, accounting for 23% of
cases during 1993 (Table 6). Blood transfusion ac-
counted for 2% of cases, declining from 6% in 1990; con-
tact with another infected person accounted for 5%,
Figure 4. Trends in Selected Risk Factors for Patients Reported with
Hepatitis B by Mutually Exclusive Groups, females, Selected States, 1983-93
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and health-care employment for
4%. Of those patients reporting
health-care employment, the per-
centage reporting frequent (several
times weekly) blood contact
dropped over 1990 to 1993. Fifty-
seven percent of patients em-
ployed in health-care reported
frequent blood contact in 1990. By
1993, the percentage dropped to
17%. Patients classified as having
multiple (2 or more) sex partners
as their most likely source of infec-
tion accounted for 7% of the pa-
tients with hepatitis C/NANB; in a
case-control study, this risk factor
was associated with acquiring dis-
ease (12). Overall, 58% of persons
reported no known source for their
infection. This percentage varied
by age, with 70% of persons
younger than 15 years old or 40 years old and older re-
porting no known source for their infection, compared
with 50% for persons 15-39 years of age. Among per-
sons less than 15, 13.6% had a history of blood transfu-
sion. 
 Among persons 15 to 39 years of age, injection drug
use was reported by 28% of all cases during 1993, un-
changed from 1992 (Table 6). Ten percent reported mul-
tiple sex partners, 7% reported contact with another
infected person, 4% reported health-care employment,
and 1% reported blood transfusions. Of reported con-
tacts with another infected person, an average of 59%
were sexual contacts, 16% were household nonsexual
contacts, and 25% were other (unspecified) types of
contact. In prior years, persons 40 years old and older
reported a history of blood transfusion most frequently
among their risk factors (in 1990, 16%), but this percent-
age declined substantially to 4% by 1993. Injection
drug use is now the most frequent risk factor for this
age-group (Table 6). 
Because total numbers of cases of hepatitis
C/NANB have declined, trends in the distribution of
risk factors are more accurately reflected by trends in
the absolute numbers of cases attributed to each factor.
In the core states, hepatitis C/NANB cases attributable
to drug use have declined rapidly since 1988, showing
a more than 62% decrease (Figure 5). A similar de-
crease of over 50% was seen in the Sentinel Counties
Study (14). 
The numbers of hepatitis C/NANB cases attribut-
able to blood transfusions have decreased even more
dramatically, dropping by 94% from 1985 to 1993. The
significant decline in transfusion-associated cases,
Percentage of Patients By Age (years)
Epidemiologic Characteristics for Prior 6 weeks by
Mutually Exclusive Groups*
Total <1-14 15-39 40+
N = 856+ N = 30 N = 557 N = 260
Blood transfusion 2.3 13.6 0.9 4.3
Injection drug use 22.6 0.0 28.4 12.0
Employed in medical/dental field 3.9 0.0 3.8 4.6
Hemodialysis 0.7 0.0 0.2 1.9
Personal contact with hepatitis C/NANB patient 5.3 6.7 7.2 1.2
Multiple sex partners 7.4 0.0 9.9 3.1
Unknown 57.8 79.7 49.6 72.9
Clinical characteristics
Jaundice 66.9 75.0 69.6 60.1
Hospitalized for hepatitis 32.9 32.1 28.8 41.7
Death as a result of hepatitis 1.9 0.0 0.8 4.5
* In decreasing order of exclusion.
+ Number includes age unknown.
Source: Viral Hepatitis Surveillance Program
Table 6. Epidemiologic and Clinical characteristics of Patients Reported with Hepatitis C/Non-A, Non -B Hepatitis, by Age
Group, United States, 1993
Figure 5. Trends in Selected Risk Factors for Patients Reported with
Hepatitis C/NANB, by Mutually Exclusive Groups, Selected States, 1983-93
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which began in the mid- 1980s, resulted from a series
of events: changes in the blood donor population
caused by self-exclusion of high-risk donors, as part of
efforts to prevent HIV infection (15,16); the introduc-
tion of screening blood donors for alanine aminotran-
ferase and anti-HBc as surrogate markers for hepatitis
C/NANB in 1986 and 1987; and use of first- and sec-
ond-generation anti-HCV markers for screening do-
nors in 1990 to the present. 
Jaundice was reported as a clinical symptom in 67%
of reported hepatitis C/NANB patients in 1993 (Table
6). Hospitalization and case-fatality rates were higher
in hepatitis C/NANB patients than in patients with
hepatitis A or B. Those 40 years old and older experi-
enced the highest rates. 
The majority of NANB hepatitis cases in this coun-
try are caused by the hepatitis C virus (14); the remain-
der are probably due mostly to other bloodborne hepa-
titis agents. Outbreaks of hepatitis E, an enterically
transmitted form of hepatitis NANB, have been re-
ported in rural Mexican villages (17), as well as in Asia
and North and West Africa (18), but no outbreaks have
been reported in this country (19). In the United States
and other countries where hepatitis E outbreaks have
not been documented to occur, rare hepatitis E cases
have been reported, primarily among travelers return-
ing from HEV-endemic regions (20). No secondary
transmission to family members or other persons in as-
sociation with these cases has been reported. In the
United States, hepatitis E cases have been reported
with no history of travel to HEV-endemic areas; how-
ever, the mode of HEV transmission for these cases has
not been determined.
Discussion
Viral hepatitis surveillance in 1993 revealed several
important changes from earlier years. First, total cases
reported to the VHSP declined more than 51% from
1990 to 1993, as a result of both real declines in the inci-
dence of hepatitis A and B, and a number of states that
previously reported now submitting fewer or none of
their cases to the VHSP. Second, the use of serologic
tests to diagnose the specific type of hepatitis has de-
clined, with fewer reported cases being diagnosed on
the basis of tests for both hepatitis A and B. Third,
analysis of trends in risk factors for the acquisition of
the different types of hepatitis indicated that injection
drug use has declined dramatically for hepatitis A, B,
and hepatitis C/NANB. Finally, more widespread use
of hepatitis B vaccine may be having an effect on the
number of hepatitis B cases acquired by heterosexual
activity. 
Underreporting and incomplete case ascertainment
are potential sources of inaccuracy and may lead to in-
accurate conclusions from surveillance data, particu-
larly in the relative frequencies of reported risk factors
(21). Since case ascertainment is dependent on the avail-
ability of sensitive and specific serologic tests, esti-
mates of the frequency of disease types such as
hepatitis C/NANB, for which there are no markers of
acute disease, are likely to be the least reliable. The
analysis of VHSP data on biases in the reporting of
hepatitis B and hepatitis C/NANB showed that consis-
tent reporting practices are critical for the accurate in-
terpretation of surveillance data in this country. In
addition, national data are averaged over many re-
gions with potentially large geographic differences in
risk factors and disease incidence. Therefore, the over-
all frequencies of various risk factors may not reflect
their importance in smaller geographic areas.
Despite the drawbacks associated with a passive
surveillance system, the data collected through the
VHSP are essential for monitoring trends in the
epidemiologic characteristics of the various types of vi-
ral hepatitis. These data are also valuable for monitor-
ing the impact of prevention programs on disease in
various high-risk groups, such as those targeted to re-
ceive hepatitis B vaccine. The recently recommended
program for the universal immunization of infants for
hepatitis B was the direct result of the analysis of sur-
veillance data, and provides evidence that contributors
to the VHSP have made a positive impact on public
health. 
Many dedicated public health practitioners, local
medical authorities, and public health communities
contribute to this surveillance system through their
timely diagnosis and reporting of hepatitis cases. We
are grateful for their continued participation and en-
courage them to continue to improve their use of sero-
logic testing, their consistency in reporting, and the
quality of the information they provide.
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Appendix (Form CDC 53.1 Rev. 8-89) 
State and Territorial Epidemiologists and
Laboratory Directors 
Key to all disease surveillance activities are the state and territorial epidemiologists and laboratory directors. The
epidemiologists and laboratory directors listed below were in the positions shown as of June 1995.
State/Territory Epidemiologist Laboratory Director 
Alabama John P. Lofgren, MD William J. Callan, PhD 
Alaska John P. Middaugh, MD Gregory V. Hayes 
Arizona Lawrence Sands, DO, MPH Barbara J. Erickson, PhD 
Arkansas Thomas C. McChesney, DVM Michael G. Foreman 
California Duc J. Vugia, MD, MPH Michael G. Volz, PhD 
Colorado Richard E. Hoffman, MD, MPH Ronald L. Cada, DrPH 
Connecticut James L. Hadler, MD, MPH Sanders F. Hawkins, PhD 
Delaware A. LeRoy Hathcock, PhD Mahadeo P. Verma, PhD 
District of Columbia Martin E. Levy, MD, MPH James B. Thomas, ScD 
Florida Richard S. Hopkins, MD, MSPH E. Charles Hartwig, ScD 
Georgia Kathleen E. Toomey, MD, MPH Elizabeth A. Franko, DrPH 
Hawaii Richard L. Vogt, MD Vernon K. Miyamoto, PhD 
Idaho Jesse F. Greenblatt, MD, MPH Richard H. Hudson, PhD 
Illinois Byron J. Francis, MD, MPH David F. Carpenter, PhD 
Indiana Edmundo M. Muniz, MD, PhD, Msc Barbara Wilder (Acting) 
lowa M. Patricia Quinlisk, MD, MPH W. J. Hausler, Jr, PhD 
Kansas Andrew R. Pelletier, MD Roger H. Carlson, PhD 
Kentucky Reginald Finger, MD, MPH Thomas E. Maxson, DrPH 
Louisiana Louise McFarland, DrPH Henry B. Bradford, Jr, PhD 
Maine Kathleen F. Gensheimer, MD, MPH Philip W. Haines, DrPH 
Maryland Diane M. Dwyer, MD J. Mehsen Joseph, PhD 
Massachusetts Alfred DeMaria, Jr, MD Ralph J. Timperi, MPH 
Michigan Kenneth R. Wilcox, Jr, MD, DrPH Robert Martin, DrPH 
Minnesota Michael T. Osterholm, PhD, MPH Pauline Bouchard, JD, MPH 
Mississippi Mary Currier, MD, MPH Joe O. Graves, PhD 
Missouri H. Denny Donnell, Jr, MD, MPH Eric C. Blank, DrPH 
Montana Todd D. Damrow, PhD, MPH Douglas O. Abbott, PhD 
Nebraska Thomas J. Safranek, MD John D. Blosser 
Nevada Randall L. Todd, DrPH Arthur F. DiSalvo, MD 
New Hampshire M. Geoffrey Smith, MD, MPH Veronica C. Malmberg, MSN 
New Jersey Kenneth C. Spitalny, MD Shahiedy I. Shahied, PhD 
New Mexico C. Mack Sewell, DrPH, MS Loris W. Hughes, PhD 
New York City Benjamin A. Mojica, MD, MPH Stanley Reimer 
New York State Dale L. Morse, MD, MS Lawrence S. Sturman, MD, PhD 
North Carolina J. Newton MacCormack, MD, MPH Samuel N. Merritt, DrPH 
North Dakota Larry A. Shireley, MS, MPH James D. Anders, MPH 
Ohio Thomas J. Halpin, MD, MPH Kathleen L. Meckstroth, DrPH 
Oklahoma Joe P. Mallonee, MPH (Acting) Garry L. McKee, PhD 
Oregon David Fleming, MD Michael R. Skeels, PhD, MPH 
Pennsylvania James T. Rankin, Jr, DVM, PhD, MPH Bruce Kieger, DrPH 
Rhode Island Barbara A. DeBuono, MD, MPH Walter Combs, PhD 
South Carolina James J. Gibson, MD, MPH Harold Dowda, PhD 
South Dakota Susan E Lance, DVM, MPH Richard S. Steece, PhD 
Tennessee Kerry Gateley, MD Michael W. Kimberly, DrPH 
Texas Diane M. Simpson, MD, PhD David L. Maserang, PhD 
Utah Craig R. Nichols, MPA Charles D. Brokopp, DrPH 
Vermont Robert O’Grady (Acting) Burton W. Wilke, Jr, PhD 
Virginia Grayson B. Miller, Jr, MD James L. Pearson, DrPH 
Washington Paul Stehr-Green, DrPH, MPH Jon M. Counts, DrPH 
West Virginia Loretta E. Haddy, MA, MS Frank W. Lambert, Jr, DrPH 
Wisconsin Jeffrey P. Davis, MD Ronald H. Laessig, PhD 
Wyoming Gayle L. Miller, DVM, MPH Carl H. Blank, DrPH 
American Samoa Julia L. Lyons, MD, MPH     — 
Federated States of Micronesia Vacant     — 
Guam Robert L. Haddock, DVM, MPH Jeff Benjamin (Acting) 
Marshall Islands Tony de Brum     — 
Northern Mariana Islands A. Mark Durand, MD, MPH     — 
Palau Jill McCready, MS, MPH     — 
Puerto Rico Carmen C. Deseda, MD Adolpho Firpo-Betancourt, MD 
Virgin Islands Donna M. Green, MD Norbert Mantor, PhD
